Why we invested
An adverse FDA ruling nearly hobbled 23andMe. Rather than succumb, Anne and her team proved resilient, eventually becoming the only company with FDA clearance to provide genetic health testing reports directly to consumers. This tenacity and product advantage, combined with an unrivaled and growing dataset, positioned 23andMe to become an early stage therapeutics platform with vast potential.
- Scientist I, Flow Cytometry
- Sr. Product Manager, Telehealth
- Associate Scientist / Sr. Associate Scientist, Antibody and Protein Engineering